-+ 0.00%
-+ 0.00%
-+ 0.00%

Pro Medicus (ASX:PME) Shares Could Be Overvalued On Its AI Imaging Update

Simply Wall St·11/18/2026 23:18:56
Listen to the news

Pro Medicus has delivered a powerful long term share price run, even as recent months have been more mixed, which puts a spotlight on whether its current valuation still lines up with the earnings behind it. With investors watching both product updates and price swings, the live question is how much of the company’s profit story is already reflected in today’s A$193.39 share price.

  • Over the past 5 years, Pro Medicus has gained 229.0%, so a lot of long term optimism is now riding on what its earnings can justify from here.
  • Visage Imaging’s AI enhanced Visage 7 platform, including the Visage 7 | Reporting rollout flagged for RSNA 2026, may support expectations for future earnings quality if it improves radiologist productivity and keeps the business embedded in large imaging workflows.
  • The analysts covering Pro Medicus have run their own numbers. See what analysts think Pro Medicus's shares could be worth.

The issue now is whether the current Pro Medicus share price is reasonable when judged purely against the earnings the business is producing today.

For context on Pro Medicus and the AI imaging theme, it can help to compare it against a wider group of 7 healthcare AI stocks.

Has Pro Medicus Run Too Far on Earnings?

The P/E ratio suits Pro Medicus because investors often focus on how much they are paying for each dollar of current earnings. At about 76.1x earnings, the stock trades at a much richer multiple than the Healthcare Services industry average of roughly 25.1x and also screens well above a peer group around 34.5x. That gap suggests buyers are already paying a sizable premium for the quality and durability of the profit stream the business produces today.

Because the modelled fair P/E, which blends the company’s growth profile, margins, sector and risk, sits below the current level, the shares screen as overvalued on this measure. The planned Visage 7 | Reporting rollout has helped frame Pro Medicus as a high productivity, AI focused imaging player. However, the present P/E still assumes that this appeal is worth paying well beyond what the company specific fair multiple framework implies. Explore the numbers behind Pro Medicus's P/E valuation.

ASX:PME P/E Ratio as at Nov 2026
ASX:PME P/E Ratio as at Nov 2026

The Pro Medicus Narrative: What Would Justify Today's Price?

Narratives on Pro Medicus pick up where the valuation puzzle leaves off by spelling out which paths for growth, profitability and earnings would need to play out for the share price to look meaningfully higher or lower than it does today on Simply Wall St's Community page. Each narrative treats fair value as a specific, testable view on how the business might perform from here so you can see how that argument holds up over time.

Pro Medicus splits opinion between product fans who see it as underappreciated and analysts who worry rich expectations leave little safety margin.

Bull case: roughly fairly valued

According to ZayaanS, a Simply Wall St Community investor who wrote the Narrative, the appeal starts with what Visage actually changes for radiologists.

"Institutions report radiologists handling 20-25% more cases on Visage than on legacy platforms, in a profession where reading hundreds of scans a day is standard..."

Discover why this Narrative puts Pro Medicus at roughly fairly valued.

Bear case: 78% overvalued

The bearish analyst Narrative on Simply Wall St frames the risk around what happens if contract economics and reported figures stop keeping up with the hype.

"Rising data sizes and usage on these cloud deployments could prompt larger clients to push back on per exam pricing in future renewals..."

Explore why this Narrative puts Pro Medicus at 78% overvalued.

One more Pro Medicus angle worth checking before you move on

Valuation, product strength and market enthusiasm only tell part of the Pro Medicus story, because recent trading disclosures point to share sales by people inside the business and the who, how much and why are still for you to review. See the recent insider selling flagged for Pro Medicus.

ASX:PME Insider Trading Volume as at Nov 2026
ASX:PME Insider Trading Volume as at Nov 2026